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Abstract Patients with ADHD may have better adher-
ence to treatment with modiﬁed-release methylphenidate
(MPH-MR) formulations, which are taken once daily,
compared with immediate-release (IR) formulations, which
need to be taken several times a day. Data on long-term
outcomes such as adherence may be lacking from ran-
domised controlled trials as these are usually only short-
term. Observational studies, if performed and reported
appropriately, can provide valuable long-term data on such
outcomes, as well as additional information on effective-
ness and efﬁciency, from a real-life setting. By reviewing
previous observational studies that have investigated
switching treatment from MPH-IR to MPH-MR, results
from a new, naturalistic observational study, the OBSEER
study, are put into context. We conclude that, based on
observational trial data, switching from MPH-IR to MPH-
MR is a valid clinical approach, with the potential for
improved clinical outcome and treatment adherence.
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Introduction
Randomised controlled trials (RCTs) in attention deﬁcit
hyperactivitydisorder(ADHD) haveshownthatlong-acting
methylphenidate (MPH) preparations have similar efﬁcacy
to multiple doses of short-acting, immediate-release (IR)
formulations, but with the advantage of convenient once-
daily dosing [4, 15, 16]. Patients receiving long-acting or
modiﬁed-release (MR), formulations may have better
treatment adherence than those receiving MPH-IR [8].
However, this is still a matter of debate as RCTs of MPH
are usually only short-term (i.e. a few weeks’ duration) and
the patient population is highly selected; therefore, results
from RCTs do not fully represent long-term treatment or
the heterogeneous population of patients with ADHD
found in daily clinical practice. To learn more about ade-
quate individualised treatment with MPH preparations in a
real-world setting, and to obtain a clearer picture of
effectiveness (‘‘is it of use?’’) and efﬁciency (‘‘how much
beneﬁt at what cost?’’), studies of treatment approaches
beyond the RCT setting are necessary [29]. The general
trend for increasing use of MPH-MR preparations in
ADHD [23, 34] means that post-RCT observational studies
are required to ensure well-monitored, up-to-date drug
management. Furthermore, there is a need for an evidence-
based, long-term perspective for patients [22].
In paediatric psychopathology, the boundaries between
‘observational’ and ‘experimental’ studies are considered
indistinct [26], with observational studies generally used
predominantly in epidemiology and less so for clinical
purposes. However, clinical observational studies may be
useful in generating additional, often more deﬁnitive,
conclusions about treatment guidance and safety effects
(especially over the long-term), or the natural history of a
disorder. Such ﬁndings can complement the results
obtained from the experimental studies [29], which are a
pre-condition for drug treatment evaluation. Thus, RCTs
and observational studies can each make a useful contri-
bution to the evaluation of treatment effectiveness.
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The RCT is seen by many as the ‘gold standard’ as it should,
by design, ensure that patients being compared differ only
in their exposure to the intervention under study [7]. In fact,
both randomised and non-randomised trial designs have
their own particular limitations. Issues related to the process
of randomisation that may affect the validity of conclusions
drawn from the results of RCTs and non-randomised studies
were explored in a systematic review [7]. Here, non-ran-
domised studies were considered to include quasi-experi-
ments, natural experiments and prospective, observational,
cohort studies. Results showed that RCTs and non-ran-
domised studies can produce different results but the
direction of the difference is not consistent—i.e. neither
method consistently favoured intervention over placebo or
new treatment over old [7]. Furthermore, neither method
gave consistently larger estimates of treatment effect.
Opposing opinions about the relative merits of RCTs and
non-randomised studies may be underpinned by differences
in threats to validity between the two study designs [7],
which can be external (the extent to which the results are
generalisable to all potential recipients), or internal (whe-
ther differences in observed effects can be attributed to
differences in the intervention) [25]. RCTs may lack
external validity in that those who meet eligibility criteria,
or are invited, or agree to participate are signiﬁcantly dif-
ferent to the population to whom the results of the study will
be applied, and so the clinical usefulness of the study may
be limited. Although evidence is limited, there is a tendency
for settings of non-randomised studies to be slightly more
representative of those who are eligible to be included [7].
Non-randomised studies also include other real-world
effects, for example patients’ preferences [25, 30], or the
doctor–patient relationship [30], increasing their external
validity. However, a major criticism of non-randomised
studies is the possibility that groups being compared differ
prognostically in important characteristics, affecting the
internal validity of such trials [7]. Clearly, for best effect,
internal and external validity need to be balanced against
each other. Interestingly, despite their methodological dif-
ferences, the systematic review found that the differences in
results between RCTs and non-randomised studies are fre-
quently smaller than those between RCTs or between non-
randomised studies [7].
Avoiding pitfalls in observational trials
As observational studies are broader in scope and less
rigorous than RCTs, they may be prone to certain pitfalls.
Observational studies, including those sponsored by
pharmaceutical companies, should be designed in such a
way that the scientiﬁc merit of the study has the highest
priority and secondary aspects are minimised [29]. To
avoid methodological shortcomings, several points need to
be considered [19], including:
• selection bias (e.g. is the sample representative for the
population in mind? Are subgroups comparable?)
• information bias (e.g. is all information gathered in a
similar way?)
• measurement errors (e.g. are inventories psychometri-
cally sound? Are measurement limitations considered?)
• evaluation problems (e.g. is the study design appropri-
ate? Is quality control of data sampling included? How
is the handling of confounders planned? Are biostatis-
tics adequate?).
Awareness of these possible pitfalls should mean that
they can be avoided by the use of an appropriate study
design, or at least that any weaknesses and limitations can
be considered when reporting and interpreting the data.
Reporting of an observational study is only as good as the
data behind it. Therefore, it would be advantageous for
investigators to consider all 22 points of the STROBE
(STrengthening the Reporting of OBservational studies in
Epidemiology) consortium checklist [1, 32] when planning
an observational study as well as when reporting it. Aside
from study design, the guidelines governing what data can
be collected in observational studies vary between coun-
tries, so what may require ethics approval in one country
would not in another. This also means that reporting these
studies can be problematic if, for example, the regulations
in the country in which the journal is published require
ethics approval even though the country in which the data
were collected did not [10].
Switching between ADHD drug treatments and patient
adherence
Treatment with MPH may improve symptoms of ADHD in
about 75% of patients, and response rates of up to 90% can
be achieved by switching unresponsive patients to other
stimulants (e.g. amphetamine sulphate) [5]. This leaves at
least 10% of patients who do not beneﬁt from stimulants,
and for whom other medications (e.g. atomoxetine, guan-
facine) may be considered. In addition, it is still not clear
how much of an improvement can be achieved if one MPH
preparation is replaced by another at an equivalent dose.
This question is of particular interest when considering a
switch from MPH-IR to MPH-MR, with the potential for
more convenient dosing, less stigmatisation and potentially
better adherence as MPH-MR only has to be administered
once daily in the morning.
S236 Eur Child Adolesc Psychiatry (2011) 20 (Suppl 2):S235–S242
123Good adherence to therapy is of utmost importance,
especially in chronic mental health conditions such as
ADHD, and must be considered in addition to the effec-
tiveness and efﬁciency of an intervention. During treatment
with MPH-IR preparations in ADHD, poor adherence is a
critical issue, ranging from 20 to 80% after 1 year, with
adherence rates of 40–50% after 3–5 years [2]. Following
parental complaints about social stigmatisation, and the
inconvenience of handling multiple doses during the day, it
was hoped that adherence would be improved by devel-
oping once-daily MPH preparations. However, better rates
of adherence do not necessarily follow from switching to
an improved formulation, as there could be other clinical
and social factors involved that are associated with the
disorganised and oppositional behaviours of patients with
ADHD and their families. For this reason, it is important to
investigate all drug- and non-drug-related aspects of
adherence when using MPH-MR preparations for the
treatment of ADHD in the daily clinical setting.
Switching of MPH preparations in observational studies
Although previous RCTs have compared MPH-IR, MPH-
MR and placebo [15, 16], such trials do not provide any
information about the clinical effects resulting from
switching from MPH-IR to MPH-MR during the study
protocol. Observational studies may be better suited to
investigating these effects, but to date only a few obser-
vational studies of switching to MPH-MR formulations
have been reported, investigating the switch to treatment
with OROS
  MPH (Concerta
 , Janssen-Cilag, UK) [27],
MPH-SODAS
  (Ritalin
 -LA, Novartis, US) [24], Medi-
kinet
  retard/XL (Medice, Germany) [13] and Equasym
XL
 1 (Shire Pharmaceuticals Ireland Limited, Ireland)
[11, 12].
One of the open-label studies was a multicentre, Euro-
pean study of OROS
  MPH, which included 150 children
(aged 6–16 years) with ADHD who were stable on MPH-
IR treatment before switching [27]. The German subgroup
of 50 patients was increased afterwards to 221 patients and
data were analysed separately [20, 21]. In the ﬁrst 3-week
phase (European and German study), children beneﬁted
from switching formulations, but IOWA Conners scores
improved only for parent ratings; teachers did not recog-
nise a change in behaviour. The global effectiveness
evaluation was positive, i.e. ‘very good’ or ‘good’ (German
study: teachers 55%, investigators 77%, parents 79%) [20].
Tolerability of OROS
  MPH was also good, with about
90% of parents favouring continuation of the MPH switch,
a good predictor for better adherence in the long-term.
These results are notable because the preceding treatment
with MPH-IR had already reduced the symptoms of
ADHD. For comparison, a score of 10 is usual on the
parent IOWA Conners scale inattention/hyperactivity for
unmedicated children with ADHD [20]. In the OROS
 
MPH study, the baseline score (i.e. after treatment with
MPH-IR, but before switching to MR) was 6.4, which
decreased further to 4.2 after 21 days of treatment with
OROS
  MPH. Thus, switching resulted in an additional
statistically signiﬁcant and clinically relevant treatment
effect [20]. However, one should be cautious about draw-
ing ﬁrm conclusions: this was an open study, the starting
dose was heterogeneous and there was a tendency to
increase doses while switching (which may be interpreted
as dose optimisation). Also, the discrepancy between par-
ent and teacher evaluation in the IOWA Conners scale may
be due to both a pharmacokinetic weakness of the OROS
 
MPH formulation in the morning (lower MPH availability)
and a pharmacokinetic strength in the afternoon (better
symptom control). In summary, one can agree with Heger
et al. [20] that ‘the results of this German sample suggest
that children and adolescents with ADHD achieve at least
as good control of central ADHD symptoms if there is a
switch from MPH-IR to OROS
  MPH’.
In the framework of the above-mentioned international
study, 89/101 (88%) patients with ADHD continued to
receive open but controlled (visit every 2nd month) treat-
ment during a 12 month extension [21]. A total of 56
children (63%) continued treatment until the end of the
extension period. Compliance with treatment was assessed
using questionnaires for parents and investigators, but no
IOWA Conners data are available. Tolerability of treat-
ment was still good and parents (* 50%) and investigators
(* 75%) gave positive feedback. Unfortunately, adher-
ence decreased by about half during the year, indicating
that drop-out rates for this MPH-MR preparation differed
little compared with the usual drop-out rates for IR prep-
arations [17, 33]. Hence, the predicted long-lasting
improvement in adherence with MPH-MR preparations
was not observed in this study. However, it is important to
also take into account the other beneﬁts of switching from
MPH-IR to MPH-MR preparations; e.g. it has been sug-
gested that MPH-MR may be less prone to misuse or abuse
compared with MPH-IR [31].
In an observational study in Brazil, patients with ADHD
were switched from clinically stable MPH-IR treatment to
MPH-SODAS
  [24]. With its 8-week duration, the study
provided information about effectiveness and satisfaction
1 Equasym XL is the UK trade name, and is registered and marketed
by Shire in the following countries under the following trademarks:
Denmark, Equasym Depot; Finland, Equasym Retard; France,
Quasym LP; Germany, Equasym Retard; Ireland, Equasym XL;
Netherlands, Equasym XL; Norway, Equasym Depot; Sweden,
Equasym Depot; South Korea, Metadate CD; Mexico, Metadate
CD. Information correct at August 2011.
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 , but not about long-term adherence.
As for the above-mentioned study with OROS
  MPH, no
information was given about the reason for switching. It is
probable that clinically stable patients were just asked if
they would like to take part in the planned study, so that
both of these observational trials were ‘real life’ but not
fully ‘naturalistic’. This is in contrast to the OBSEER
(OBservation of Safety and Effectiveness of Equasym XL
 
in Routine care) study reported in this supplement [12], the
ADORE study [29], and a study on the effects of ato-
moxetine on ADHD in clinical paediatric treatment settings
[3], which can all be considered as naturalistic—i.e. it was
up to the physician which patients with ADHD were
included in the study. The MPH-SODAS
  switch study
included only a small sample of children (n = 31) and
adults (n = 23), with a protocol adherence of 70–80% after
8 weeks [24]. There were no signiﬁcant changes in behav-
ioural parameters and side-effects on MPH-SODAS
 , but
the majority of patients were reported to be satisﬁed with
switching (74%). The authors stated that the latter ‘‘may
reﬂect the convenience of once-daily dosing of this MPH-
extended release, as speculated in previous studies’’ [24],
referring to a study in Taiwan [18].
Further publications from this Taiwanese research group
[9, 17] looked at children with ADHD who adhered poorly
to MPH-IR treatment and who were offered the chance to
switch to MPH-OROS
 . Of 607 children with ADHD aged
5–16 years, 240 (40%) were poorly adherent to treatment.
A ﬁnal subgroup of 124 children (originally 137; 13 were
lost to follow-up) switched to MPH-OROS
  and showed
superior adherence and improved efﬁcacy over a period of
3 weeks in an intra-individual comparison of MPH-IR
versus MPH-OROS
  use. This shows in principle that such
a switch appears to work, at least in the short-term
(3 weeks); however, only about half of the poor adherents
to medication seemed to accept the offer. Reasons for, and
determinants of, poor adherence may partly explain this
observation (Table 1). This underlines the idea that the
switch of MPH preparations itself (from MPH-IR to MPH-
MR in this case) is not the only factor affecting treatment
adherence. Furthermore, switching preparations is usually
accompanied by dosage increases and closer monitoring.
AswitchtoMedikinet
 retard/XL(long-actingMPHwith
50% MPH-IR) was explored in an open-label study of 447
patients (aged 6–17 years) who were either untreated (but
consideredsuitableforsuchtreatment)orcurrentlyreceiving
maintenance treatment with an approved MPH dosage form
(IR or MR) [13]. Primary outcome measures were ADHD
severityandsideeffects,whichwereevaluatedbyphysicians
and parents at the time of the medication changeover and
4–6 weeks later. ADHD symptom severity declined signif-
icantly, and oppositional behaviour and side effects, as
assessed by parents, were also reduced. As expected, the
strongest effects were found in patients without prior phar-
macotherapy, but signiﬁcant improvements were also
observedinpatientswithonce-dailyormorethanonce-daily
MPH-IR as prior medication, as well as Concerta
 .
Similarly, a switch to Equasym XL
  was analysed in
another open-label study performed in children aged
6–17 years, either untreated or currently receiving main-
tenance treatment with a different MPH formulation [11].
The majority (65%) of the 308 patients enrolled demon-
strated a positive response, which was also observed within
the group who were previously treated with MPH-IR (64%)
and those treated with a different MPH-MR formulation
(55%). Most patients (87%) were very or moderately sat-
isﬁed with treatment.
Further results supporting a switch to MPH-MR for-
mulations were obtained in the German multicentre, pro-
spective, observational, naturalistic OBSEER study on the
safety and effectiveness of Equasym XL
 , and are reported
in this supplement [6, 12, 14, 28]. OBSEER, planned and
reported in line with the STROBE criteria (Table 2), col-
lected behavioural data over a period of about 12 weeks
from 822 children aged 6–17 years with ADHD. A total of
574 (70%) children had been treated previously with other
MPH formulations such as MPH-IR or MPH-MR. The
treating physician decided independently, on the basis of
his clinical assessment and experience, if treatment with
Equasym XL
  should be started. Therefore, the children
did not need to be clinically stable on MPH-IR, as in the
other switching studies described above. A subgroup of
children (n = 371, 45%) was switched from MPH-IR
(once-daily: n = 101, 12%; repeated [i.e. administered
several times per day]: n = 270, 33%) to MPH-MR. These
children showed an improvement in all parameters inves-
tigated, including symptom reduction, satisfaction with
treatment and quality of life [14, 28]. The MPH-IR once-
daily prior treatment subgroup showed improvements in
adherence rates during Equasym XL
  treatment that were
Table 1 Reasons for, and determinants of, poor adherence to MPH-
IR treatment
Reasons (patients/parents
report)
Determinants (univariate analysis)
Forgetting medication Older age
Side effects/safety concerns Increased frequency of drug
administration
Lack of perceived effect Older age at onset/diagnosis
Privacy issues Family history of ADHD
Bitter taste Higher paternal education
Teacher objection Higher mean dose of MPH
Switch to MPH-OROS
  was based mainly on the decision of the
investigator after mutual discussion with patients and their parents
(according to Gau et al. [17])
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Item
No
Recommendation
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 4
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 4
Introduction
Background/
rationale
2 Explain the scientiﬁc background and rationale for the investigation being reported 4
Objectives 3 State speciﬁc objectives, including any prespeciﬁed hypotheses 4
Methods
Study design 4 Present key elements of study design early in the paper 4
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up,
and data collection
4
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants.
Describe methods of follow-up
Case–control study—Give the eligibility criteria, and the sources and methods of case ascertainment and
control selection. Give the rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants
4
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed
Case–control study—For matched studies, give matching criteria and the number of controls per case
Variables 7 Clearly deﬁne all outcomes, exposures, predictors, potential confounders, and effect modiﬁers. Give
diagnostic criteria, if applicable
4
Data sources/
measurement
8
a For each variable of interest, give sources of data and details of methods of assessment (measurement).
Describe comparability of assessment methods if there is more than one group
4
Bias 9 Describe any efforts to address potential sources of bias 4
Study size 10 Explain how the study size was arrived at 4
Quantitative
variables
11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings
were chosen and why
4
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 4
(b) Describe any methods used to examine subgroups and interactions 4
(c) Explain how missing data were addressed 4
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case–control study—If applicable, explain how matching of cases and controls was addressed
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy
NA
(e) Describe any sensitivity analyses NA
Results
Participants 13
a (a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for
eligibility, conﬁrmed eligible, included in the study, completing follow-up, and analysed
4
(b) Give reasons for non-participation at each stage 4
(c) Consider use of a ﬂow diagram 4
Descriptive data 14
a (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on
exposures and potential confounders
4
(b) Indicate number of participants with missing data for each variable of interest 4
(c) Cohort study—Summarise follow-up time (e.g. average and total amount) 4
Outcome data 15
a Cohort study—Report numbers of outcome events or summary measures over time 4
Case–control study—Report numbers in each exposure category, or summary measures of exposure
Cross-sectional study—Report numbers of outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g.
95% conﬁdence interval). Make clear which confounders were adjusted for and why they were included
4
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses 4
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MR or ‘other/not speciﬁed’), and a particular advantage
was noted for the MPH-IR repeated prior treatment sub-
group [28]. The positive effects were reﬂected by infor-
mation from parents, teachers, children and physicians, and
results were stable all day long. As in the other MPH-IR to
MR switch studies, the dosage of MPH increased slightly
following the transition. Interestingly, improvements were
also noted in the subgroup of patients who switched from a
different MPH-MR formulation to Equasym XL
 , although
these were less marked than for the MPH-IR subgroups, as
might be expected [14, 28].
Conclusions
Data from observational studies indicate that switching
from one MPH preparation to another, speciﬁcally from
MPH-IR to MPH-MR, but even from one MPH-MR for-
mulation to another, appears to be a valid clinical approach
that may contribute to treatment success. The observed
improvement in various treatment outcomes might be best
explained by the following factors: ﬁrst, by the increased
(and thus optimised) dose of MPH; second, the shorter
intervals between visits directly after switching, leading to
more intense psycho education and guidance; third, a
positive expectation of improvement by all participants;
and fourth, there might be an improvement in adherence in
the long-term (short-term improvements have been shown
[9, 17]) accompanied by better general success of treat-
ment, but this requires clariﬁcation in controlled studies.
In summary, within the framework of successful drug
management of children and adolescents with ADHD,
observational studies are necessary to reﬁne the results and
recommendations derived from RCTs, and enable further
progress towards individualised medication.
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